Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment has been widely exploited as an active participant in tumor progression. Extensive reports have defined the dual role of tumor-associated macrophages (TAMs) in tumor development. The protumoral effect exerted by the M2 phenotype has been correlated with a negative outcome in most solid tumors. The high infiltration of immune cells in the hypoxic cores of advanced solid tumors leads to a chain reaction of stimuli that enhances the expression of protumoral genes, thrives tumor malignancy, and leads to the emergence of drug resistance. Many studies have shown therapeutic targeting systems, solely to TAMs or tumor hypoxia, however, novel therapeutics that target both features are still warranted. In the present review, we discuss the role of hypoxia in tumor development and the clinical outcome of hypoxia-targeted therapeutics, such as hypoxia-inducible factor (HIF-1) inhibitors and hypoxia-activated prodrugs. Furthermore, we review the state-of-the-art of macrophage-based cancer therapy. We thoroughly discuss the development of novel therapeutics that simultaneously target TAMs and tumor hypoxia. Nano-based systems have been highlighted as interesting strategies for dual modality treatments, with somewhat improved tissue extravasation. Such approach could be seen as a promising strategy to overcome drug resistance and enhance the efficacy of chemotherapy in advanced solid and metastatic tumors, especially when exploiting cell-based nanotherapies. Finally, we provide an in-depth opinion on the importance of exploiting the tumor microenvironment in cancer therapy, and how this could be translated to clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 1×
“They are highly accumulated in poorly vascularized, hypoxic and necrotic areas, contributing to a poor prognosis and exerting a protumoral effect in many types of solid tumors [96, 97].”
BackgroundTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 1×
“Chemotactic cytokines, such as CXCL1, CXCL8, CXCL12, CXCL13, CCL5, are used to attract circulating monocytes to the tumor microenvironment [89-91].”
BackgroundTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“The choice of which reduction occurs depends on the structure of the compound itself and the differential expression of reducing enzymes in tissues [20,54].”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“However, the associated side effects and the emergence of multidrug resistance (MDR), have limited the clinical use of most common therapeutic compounds [8].”
BackgroundImmune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · cited 2×
“This escape is due to the development of deficiencies in antigen processing and presentation in several MAC pathways, and the consequent production of immune suppressive cytokines [88].”
BackgroundRies, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Macrophages in Tumor Microenvironments and the Progression of Tumors
Hao, N.-B., Lü, M.-H., Fan, Y.-H., Cao, Y.-L., Zhang, Z.-R., & Yang, S.-M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/948098 · Cited by 1,003 · cited 1×
“They over-express scavenger receptors, mannose receptors and exhibit anti-inflammatory activity [94,95].”
Background“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792 · cited 1×
“They over-express scavenger receptors, mannose receptors and exhibit anti-inflammatory activity [94, 95].”
BackgroundDigoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624
Ahsan, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00549-1 · Cited by 570 · cited 1×
“They have an important immunosurveillance role, mainly responsible for tissue repair, wound healing and defense against pathogens, including tumor cells [85].”
BackgroundTumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
Swartz, M. A., Iida, N., Roberts, E. W., Sangaletti, S., Wong, M. H., Yull, F. E., Coussens, L. M., & DeClerck, Y. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0122 · Cited by 542 · cited 1×
“Studies have shown that cancer cells evolved to promote angiogenesis, metastasis and survival in response to several factors within the tumor microenvironment, such as pH, growth factors, oxygen levels and the presence of immune cells [3-5].”
BackgroundMacrophage Responses to Hypoxia
Lewis, C., & Murdoch, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62038-x · Cited by 413 · cited 1×
“HIF-1 transcription factor not only modulates the expression of cancer-related genes in TAMs, but also provokes a metabolic shift in these immune cells, thriving the tumor development under nutrient and oxygen deprivation [130].”
BackgroundLayer-by-Layer Nanoparticles with a pH-Sheddable Layer for in Vivo Targeting of Tumor Hypoxia
Poon, Z., Chang, D., Zhao, X., & Hammond, P. T. (2011) · ACS Nano · doi:10.1021/nn200876f · Cited by 343
Tumour-on-a-chip provides an optical window into nanoparticle tissue transport
Albanese, A., Lam, A. K., Sykes, E. A., Rocheleau, J. V., & Chan, W. C. W. (2013) · Nature Communications · doi:10.1038/ncomms3718 · Cited by 330 · cited 1×
“Nevertheless, biomimetic ‘organ/ tumor-on-a-chip’ tools have presented themselves as promising new in vitro tools, that could bring together the advantages of tumor spheroids [151], with the aid of microfluidic systems that can offer”
BackgroundKoh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
Development of HIF‐1 inhibitors for cancer therapy
Onnis, B., Rapisarda, A., & Melillo, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00876.x · Cited by 268
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0510 · Cited by 245
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2116 · Cited by 187
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0274 · Cited by 171
Zhan, X., Jia, L., Niu, Y., Qi, H., Chen, X., Zhang, Q., Zhang, J., Wang, Y., Dong, L., & Wang, C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.09.007 · Cited by 161
Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2362-z · Cited by 159 · cited 1×
“del ivery In vitro s tudies in prostate cancer and glioblastoma showed [37-40] ACCEPTED MANUSCRIPT”
BackgroundHypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140 · cited 3×
“Therefore, substantial efforts have been made to develop more reliable in vitro methods that can then be successfully translated to in vivo set-up and in patients [30].”
BackgroundInfluentialHicks, K. O., Siim, B. G., Jaiswal, J. K., Pruijn, F. B., Fraser, A. M., Patel, R., Hogg, A., Liyanage, H. D. S., Dorie, M. J., Brown, J. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1439 · Cited by 132
DiSilvestro, P. A., Ali, S., Craighead, P. S., Lucci, J. A., Lee, Y.-C., Cohn, D. E., Spirtos, N. M., Tewari, K. S., Muller, C., Gajewski, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4265 · Cited by 127 · cited 9×
“13 randomized clinical trial combining radiation and cisplatin, with TPZ, for cervical cancer (Phase III) [58], showed that the combined ACCEPTED MANUSCRIPT”
BackgroundInfluentialLiu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1852-8 · Cited by 113 · cited 1×
“Phase I/II clinical trials have shown promising results for the drug as both a single agent and in combinatorial treatments with gemcitabine and nab-paclitaxel for pancreatic cancer [67,68,76].”
BackgroundJacoby, J. J., Erez, B., Korshunova, M. V., Williams, R. R., Furutani, K., Takahashi, O., Kirkpatrick, L., Lippman, S. M., Powis, G., O'Reilly, M. S., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181dc211f · Cited by 84
Kurzrock, R., Goel, S., Wheler, J., Hong, D., Fu, S., Rezai, K., Morgan‐Linnell, S. K., Urien, S., Mani, S., Chaudhary, I., et al. (2012) · Cancer · doi:10.1002/cncr.27647 · Cited by 50
Development of a nanoparticle-based system for the delivery of retinoic acid into macrophages
Almouazen, E., Bourgeois, S., Boussaïd, A., Valot, P., Malleval, C., Fessi, H., Nataf, S., & Briançon, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.025 · Cited by 47 · cited 1×
“Flow cytometry andfluorescentmicroscopy analysis demonstrated that these nanocarriers were efficiently taken up by MACs, following systemic administration and remained engulfed in TAMs for 7 days [126].”
BackgroundPatnaik, A., Chiorean, E. G., Tolcher, A., Papadopoulos, K., Beeram, M., Kee, D., Waddell, M., Gilles, E., & Buchbinder, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2564 · Cited by 26
Cited by
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Yang, M., Li, J., Gu, P., & Fan, X. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 670
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
Peng, S., Xiao, F., Chen, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202103836 · Cited by 441
Overchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
Metadata
- Authors
- Silva, V. L., & Al-Jamal, W. T.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 253
- Pages
- 82-96
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2593378954
- Cited by
- 78
- References
- 34
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.